Lantheus Holdings, Inc. (LNTH)
Sector: Healthcare
Industry: In Vitro & In Vivo Diagnostic Substances
Country: United States
Exchange: NASDAQ
Market cap: $6.57B
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Latest financial period: June 30, 2026
Filed with the SEC: August 6, 2026
Estimated earnings date: November 5, 2026
Not currently ranked. Cannot calculate: FCF yield
Profit Not currently ranked
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | 24.4% | 27.5% | 30.8% | 30.4% |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
